A prescription app, Rejoyn, for adults with major depression receiving interventional treatment
Observes how adults with major depressive disorder use the Rejoyn app alongside treatment.
Plain-language title generated from the registry record
Registry title: REWIRE: Real-world Engagement With Interventional and Rejoyn Effectiveness
Key facts
- Where
- Greenwich and New Haven, United StatesSee the 2 sites
Where in United States
- Yale Greenwich Hospital Interventional Psychiatry ServicesGreenwich, United StatesNo longer taking part
- Yale New Haven Hospital Interventional Psychiatry ServicesNew Haven, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Yale University
- Trial code
- NCT07792252
- Record updated
- 9 September 2026
- Original description
Rejoyn is a Prescription Digital Therapeutic (PDT) for adults with Major Depressive Disorder (MDD). This study aims to evaluate the feasibility, engagement, and clinical context of integrating Rejoyn into standard interventional workflows at the Yale New Haven Hospital Interventional Psychiatry Service (IPS). This is a non-significant risk, observational real-world evidence (RWE) study.Read full original descriptionShow less
A Prospective Observational Real-World Evidence Study of a 510(k)-Cleared Prescription Digital Therapeutic in Patients Receiving Interventional Treatment for Major Depressive Disorder
Rejoyn is a Prescription Digital Therapeutic (PDT) for adults with Major Depressive Disorder (MDD). This study aims to evaluate the feasibility, engagement, and clinical context of integrating Rejoyn into standard interventional workflows at the Yale New Haven Hospital Interventional Psychiatry Service (IPS). This is a non-significant risk, observational real-world evidence (RWE) study.
Inclusion: Clinician-confirmed diagnosis of Major Depressive Disorder; Currently being treated with an antidepressant medication; Currently receiving or initiating TMS or esketamine at YNHH IPS; For those receiving TMS, they must be able to initiate Rejoyn within the first two weeks of beginning TMS; Experiencing at least mild depressive symptoms as defined by QIDS of ≥6; Clinician determines patient is appropriate for Rejoyn and prescribes it as part of standard care; Able to access and use a compatible smartphone; Able to provide informed consent for use of clinical data in research.
Exclusion: Concurrent participation in another interventional study that would interfere with naturalistic data; Significant cognitive impairment that prevents app use; Clinician determines Rejoyn is not suitable or safe for the patient; Insufficient English proficiency to use Rejoyn.